Bokus

James Leong – författare

Visar alla böcker från författaren James Leong. Handla med fri frakt och snabb leverans.

3 produkter

  1. James Leong, Sam Salek, Stuart Walker - Benefit-Risk Assessment of Medicines, Inbunden. Tillgänglighet: Lägg i varukorg

    Benefit-Risk Assessment of Medicines

    The Development and Application of a Universal Framework for Decision-Making and Effective Communication

    Av James Leong, Sam Salek m. fl.

    Inbunden, 2015

    568 kr

    Lägg i varukorg

    This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox.Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the …

  2. Stuart Walker, Sam Salek, James Leong - Benefit-Risk Assessment of Medicines, E-bok. Tillgänglighet: Lägg i varukorg

    Benefit-Risk Assessment of Medicines

    The Development and Application of a Universal Framework for Decision-Making and Effective Communication

    Av Stuart Walker, Sam Salek m. fl.

    E-bok, 2015

    755 kr

    Lägg i varukorg

    This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox. Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the …

  3. James Leong, Sam Salek, Stuart Walker - Benefit-Risk Assessment of Medicines, Häftad. Tillgänglighet: Lägg i varukorg

    Benefit-Risk Assessment of Medicines

    The Development and Application of a Universal Framework for Decision-Making and Effective Communication

    Av James Leong, Sam Salek m. fl.

    Häftad, 2016

    568 kr

    Lägg i varukorg

    This book proposes and investigates a universal framework, and accompanying documentation system, to facilitate and catalogue benefit-risk decisions; a valuable addition to the benefit-risk toolbox.Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the …